Peptides for Immune Support: Thymosin Alpha-1, FORTIFY and the Evidence

A 28-amino-acid peptide cut from a larger precursor called prothymosin alpha, produced naturally by the thymus. Research describes it acting on T-cell maturation and function, on dendritic cells, which are the cells that present a captured antigen to T cells, and on Toll-like receptor signalling. The described result is a better-directed response to a specific antigen rather than a general rise in inflammatory tone.

That mechanism is why it has been studied as a vaccine adjuvant, meaning something given alongside a vaccine in populations that respond poorly. It is approved in several countries outside the United States for chronic hepatitis B, and has been studied in sepsis and critical illness with mixed results. A 2015 historical review in Expert Opinion on Biological Therapy describes its tolerability across thousands of patients as very favourable.

It is supplied as a 5 mL vial and as a pre-filled 3 mL Pen cartridge containing 15 mg.

A peptide preparation derived from thymus tissue rather than a single synthesised sequence. It sits in the same family as thymosin alpha-1 and is described as restoring immune regulation through effects on T-cell populations. Most published work is Russian clinical literature, and Western trial data is limited. Anyone presenting thymalin and thymosin alpha-1 as interchangeable is skipping a real difference in evidence quality.

The literature comes almost entirely from Vladimir Khavinson's group: a 2020 paper in the Bulletin of Experimental Biology and Medicine on cultured human stem cells, 2022 and 2023 papers in the International Journal of Molecular Sciences on cytokine output from stimulated human immune cells, and a 2021 report in Stem Cell Reviews and Reports on thymalin added to standard care in hospitalised COVID-19 patients, which was not a blinded randomised trial.

The last three amino acids, lysine-proline-valine, of alpha-melanocyte-stimulating hormone. Isolating that fragment keeps the anti-inflammatory signalling of the parent hormone without its pigmentation effect. It is described as interfering with inflammatory signalling inside the cell, including the NF-kB and MAPK pathways, which lowers output of cytokines such as TNF-alpha and IL-6. Most published work sits in models of inflammatory bowel disease and dermatitis, which is why it also appears in peptides for gut health.

The key paper is a 2008 study in Gastroenterology reporting that nanomolar KPV inhibits NF-kB signalling in human intestinal cells, enters them through the PepT1 transporter, and reduced chemically induced colitis in mice; a 2008 paper in Inflammatory Bowel Diseases reports the same in two mouse models.

The only human cathelicidin, an antimicrobial peptide released by neutrophils and by the epithelial cells lining skin, gut and airway. It is described as disrupting microbial membranes directly and as signalling to other immune cells. Research is preclinical. In FORTIFY it is present at 1 mg per vial, the smallest component by weight.

A 2006 review in Biochimica et Biophysica Acta is the standard reference. The only human trials are topical, for venous leg ulcers: a 2014 study in Wound Repair and Regeneration in 34 patients, and a 2021 phase IIb trial in 148 patients that found no difference from placebo overall. A 2007 paper in Nature identified LL-37 as the factor that lets dendritic cells respond to the body's own DNA in psoriasis, one reason a physician asks about autoimmune skin disease before prescribing anything containing it.

A 15-amino-acid fragment of a protein found in human gastric juice. It is not an immune peptide. It is in FORTIFY because mucosal surfaces, particularly the gut lining, are where a large share of immune activity happens, and BPC-157 is the compound most studied for protecting that lining. Its separate repair role is covered in what is BPC-157. There are no randomised human trials of BPC-157 for any indication.

The default when the question is immune signalling itself and the person wants the compound with human trial data. Prescribers describe it suiting adults who have been through the rule-out list below and still have unexplained frequent infection. It does not suit anyone with autoimmune disease, on immunosuppression, or in active cancer treatment.

The reviewed directions run five days a week by subcutaneous injection, with the Pen cartridge dosed three times a week. Your physician sets your dose and it is printed on the medication. The vial and the pepti Pen carry the same molecule; the Pen removes the draw step and costs more, and neither is clinically better.

FORTIFY combines thymosin alpha-1, BPC-157, KPV and LL-37, following the layers table. It is chosen when the picture is not just "I get sick often" but "I get sick often, my gut is unsettled, and things take a long time to calm down."

Two honest points. The thymosin alpha-1 content per vial is half that of the single-agent product, and the blend has not been studied as a blend; what FORTIFY offers is breadth of mechanism, not a stronger evidence base. Directions run five days a week. Full reference: what is FORTIFY.

Thymalin is the choice when the interest is specifically age-related immune decline, because that is what its literature is about. It suits an older adult without autoimmune disease whose physician is comfortable prescribing on an open-label literature; there is no human head-to-head with thymosin alpha-1. Directions run five days a week. Full reference: what is thymalin.

KPV is prescribed when the problem is not infection frequency but an inflammatory response that is not switching off, usually with a gut or skin component. There are no randomised human trials of KPV for any indication. Directions run five days a week. Full reference: what is KPV.

A 1998 randomised controlled trial in Hepatology gave 98 patients with chronic hepatitis B 26 weeks of thymosin alpha-1, 52 weeks, or no treatment. Complete virological response was 40.6 percent in the 26-week group and 9.4 percent in controls at 18 months, with the difference emerging after treatment ended. A 2008 meta-analysis in Antiviral Research of four randomised trials against interferon alpha found the same pattern of responses accumulating after treatment.

A 2026 Cochrane review of ten randomised trials with 1,349 participants is more cautious: the authors rated the certainty of evidence as very low for nearly every outcome, citing risk of bias, small numbers and heterogeneity. Consistent signals in individual trials, and a systematic review that does not consider them settled.

A 2012 trial in the Journal of Viral Hepatitis randomised 552 patients unresponsive to peginterferon and ribavirin to the same regimen plus thymosin alpha-1 or placebo. Sustained virological response overall was no different (12.7 versus 10.5 percent); among patients who completed 48 weeks it was 41 versus 26 percent. The authors concluded it has no role in primary treatment.

This is the evidence closest to what most people mean by immune support. A 1989 double-blind placebo-controlled study in the Journal of the American Geriatrics Society gave 90 men aged 65 to 99 thymosin alpha-1 or placebo alongside the influenza vaccine and measured antibody response. A 2012 pilot trial in Vaccine gave 94 hemodialysis patients a pandemic H1N1 vaccine alone or with thymosin alpha-1; both thymosin groups met the European licensing criteria for seroconversion. What that supports is a stronger antibody response to a specific vaccine in people known to respond poorly, not fewer infections in a healthy adult, and it does not replace the vaccine.

Two randomised trials from the same Chinese group disagree. ETASS, in Critical Care in 2013, was single-blind in 361 patients and reported a borderline difference on its primary outcome. TESTS, in the BMJ in 2025, was double-blind and placebo-controlled in 1,106 adults across 22 centres, and found no difference on its primary outcome or on any secondary or safety outcome. The larger, better-designed trial did not confirm the earlier signal.

A 2010 phase II study in the Journal of Clinical Oncology randomised 488 patients with metastatic melanoma to dacarbazine with or without interferon alfa and thymosin alpha-1; tumour response rates were higher in two thymosin arms. It is why it is never prescribed for immune support during active cancer treatment without the oncologist's involvement.

There are no randomised human trials of thymalin for immune support in healthy adults, none of KPV for any indication, and none of injected LL-37; LL-37's only randomised human work is topical.

• That any of these peptides reduces the number of ordinary infections a healthy adult gets in a year. That trial has not been run.
• An effect size or a timeline for immune support; the windows prescribers describe are clinical experience.
• That FORTIFY as a combination does anything its components do not do alone.
• Long-term safety over years of continuous use in healthy adults.
• Efficacy as an FDA-approved treatment. None of the four is FDA approved, and compounded medications are not FDA approved as finished products.

Thymosin alpha-1 was nominated for the FDA's 503A bulk drug substances list and for a period sat in Category 2, the category for nominated substances the agency has flagged as raising significant safety concerns. The FDA's September 2024 category list records that it was removed from Category 2 because the nomination was withdrawn by the nominator, and that the agency would consult its Pharmacy Compounding Advisory Committee on 4 December 2024 anyway.

On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 4 in favour and 17 against placing thymosin alpha-1 (free base) on the 503A Bulks List, and 4 to 17 against thymosin alpha-1 acetate. The uses reviewed included hepatitis B and C, HIV, COVID-19, depressed response to vaccination, several cancers, sepsis, COPD and ME/CFS. The minutes record that members voting no agreed there was no compelling evidence demonstrating clinical effectiveness and safety in those uses, and that members voting yes felt the substance should remain accessible to patients as an option.

That was an advisory vote. On the FDA's category list updated 14 May 2026, thymosin alpha-1 appears in none of the three categories, and the FDA's safety-risk page lists it among substances "previously in category 2" whose nominations were withdrawn. No final rule has placed it on, or excluded it from, the 503A Bulks List. It remains legal to prescribe and dispense as a compounded medication, and it is not an FDA-approved drug product.

All three were placed in Category 2 in 2023. The FDA's safety-risk page now lists BPC-157, Cathelicidin LL-37 and KPV among substances "previously in category 2" that were withdrawn by their nominators, and none appears in Category 1, 2 or 3 on the 14 May 2026 list. The removal was announced on 15 April 2026 as part of a group of twelve peptides.

On 23 July 2026 the committee reviewed BPC-157 for ulcerative colitis and KPV for wound healing and inflammatory conditions, and voted 8 in favour and 6 against, with one abstention, to recommend adding each to the 503A Bulks List. Those are recommendations; the FDA's final determinations are pending.

LL-37 was not on the July agenda. The FDA has said it will hold a further advisory committee meeting before the end of February 2027, and Cathelicidin LL-37 is among the substances named for it.

Thymalin has never been nominated for the 503A list. It appears in none of the three categories on the 14 May 2026 list and has not been before the advisory committee.

None of the four is an FDA-approved drug, and no compounded medication is: they are prepared by a state-licensed pharmacy for an individual prescription rather than approved as manufactured products. A provider describing any of these as "FDA approved" is misleading you. See are peptides FDA approved.

On the WADA 2026 Prohibited List, effective 1 January 2026, BPC-157 is named as an example under S0, the class for substances with no current approval by any regulatory health authority, prohibited at all times. FORTIFY, which contains BPC-157, is therefore prohibited for tested athletes. The other four are not named on the 2026 list, but S0 is defined by approval status rather than by name, so a tested athlete should confirm with their anti-doping organisation first.

Injection-site redness or tenderness, and for some a day or two of feeling slightly off. Nothing about the immune response itself is perceptible.

Still nothing specific. In the hepatitis B trials the virological response emerged after treatment ended, a reminder that immune effects, where they occur, are slow. Refills run every 28 days, one vial per fill, and treatment continues for as long as you and your physician agree it should.

Six infections last winter and two this winter is a real observation about you, and also exactly what a milder virus season or a child leaving daycare would produce. A physician will weigh it with you rather than treating it as proof. There is no established interaction list for any of the four, which is why every medication you take goes through a physician.